Fritextsökning
Innehållstyper
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Recipharm launches into biologics manufacturing
Recently a Swedish biomanufacturing facility transfers from Astrazeneca to Recipharm Biologics.
-
New nano professor in Denmark
The Technical University of Denmark has appointed a recognized physicist as a new professor of miniaturized sensors.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Swiss allergy therapy convinces
Cytos Biotechnology presents promising results in a study of a new therapy against allergy and asthma.
-
Steven Burrill vill starta svensk fond
Investeraren och analytikern Steven Burrill var nyligen i Sverige för besluta om han ska starta en svensk eller nordisk life science-fond. - Det finns mycket st...
-
Positive combined cancer therapy
Topotarget announces positive data with new treatment against colorectal cancer.
-
Collaboration brings next generation drugs
Wyeth and Santaris Pharma announce a new alliance to develop RNA-based medicines.
-
Test if you carry the fat virus
In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.
-
Biotech goes white and bright
White biotech could become Denmark's next blossoming business area.
-
Xbrane förbereder sig för börsen
Genom att listas på Nasdaq får bolaget tillgång till en bra kapitalplattform och ökad synlighet gentemot potentiella aktieägare, säger Martin Åmark, vd för Xbra...
-
Diagnostics for personalized medicine
Per Matsson from Phadia anticipates changes in the standards for health care. Accordiing to him, expensive new drugs will create a market for more extensive diagnostics.
-
Två steg framåt för Bioinvent
Bioinvent och partnern Trombogneics har avslutat fas I studien av cancersubstansen TB-403. Resultaten visar att substansen tolereras väl och endast ger ett fåta...
-
Focusing on Medicon Valley
Copenhagen Capacity and Invest in Skåne are hosting a seminar to promote the geographical area known as Medicon Valley. Some of the 350 life science companies f...
-
Mingling types - who to aim for and who to avoid:
Read about different mingling types - who are you?
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at app...
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
-
Bio engineering breakthrough in Denmark
Brand new research makes BioGasol's cellulosic ethanol process even more competitive.
-
A crash course in IP strategy
"Publish, publish, publish!" Sound familiar? So to meet the researcher's wishes, do you scribble a patent application with lipstick on a napkin and send it in? ...
-
Time to save for survival
The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.
-
Exhibitors
Register of exhibitors and where they can be found.
-
Ideon - Sweden's oldest science park
Old is not synonymous with boring. Swedens oldest science park Ideon still manages to attract young companies with big ideas. The recipe for success? To continu...